The National Center of Neurology and Psychiatry, based in Japan, announced that they will initiate a 3-month clinical trial on 9 patients with multiple sclerosis, beginning in March. Multiple sclerosis is an autoimmune disease caused by mutations of lymphocyte immune cells, which attack and destroy a patient’s own nerve cells. Patients with multiple sclerosis typically…
treatment
Steve Pepple / Shutterstock.com The 2012 state ballot approvals of marijuana legalization in Colorado and Washington has been a catalyst for stirring the pot, so to speak, on a wide range of issues and nuances related to the herb — not least marijuana’s clinical use as a…
Marijuana has been approved for medicinal purposes in a number of U.S. states, however it still remains a much debated issue according to the American Academy of Neurology. New information has been released by ANN Annual Meeting in Philadelphia, PA. This represents the largest gathering of neurologists globally. According…
Petah Tikvah Israel-based Teva Pharmaceutical Industries Ltd. has suffered a setback in its fight to forestall release of generic competitors for its proprietary Copaxone Multiple Sclerosis drug. However, the company is expressing optimism that potential for recovery of Patent Infringement Damages may dissuade aspirant generic competitors from proceeding until a…
Recommended Posts
- Pain linked to perceived cognitive difficulties in MS study
- Navigating mood changes in everyday life with MS
- Vitamin D-related gene changes tied to movement symptoms in MS
- Vitamin D, curcumin combination may help regulate immune cells in MS
- Stem cell transplant may help reduce chronic inflammation in MS